When ovarian and other abdominal cancers spread, they often fill the belly with fluid — a malignant ascites that doctors drain for comfort but rarely mine for answers. A new study suggests that fluid has been hiding some of the cancer’s protectors.
Reporting in Science Immunology, researchers who performed a multiomic analysis of malignant ascites identified a previously underappreciated population of immune cells — dendritic cells marked by a gene called RORC — concentrated at sites where tumors metastasise. Rather than rallying an attack on the cancer, these cells appear to help create a tolerant immune environment around it, limiting the body’s ability to strike back.
That makes them a target. The team identified pathways the cells depend on and potential therapeutic levers, and is now testing the most promising approaches in patient-derived models. If the cells’ activity can be switched off or reprogrammed, existing immunotherapies — which often fail against these cancers — might finally get through.
The population they could help is among oncology’s most underserved. Malignant ascites signals advanced disease, and the patients who develop it have few good options beyond repeated drainage and palliative care. Studying the fluid that clinicians have been throwing away turns standard care into a research asset: every drainage procedure becomes a biopsy of the tumor’s immune neighbourhood.
The researchers are clear that none of this changes treatment today. What it changes is the map. A rare cell type, invisible until someone looked at cancer through its fluid, now sits near the top of the list of reasons these tumors resist the immune system — and near the top of the list of things to switch off next.
Related reading: Real-Time Oxygen Tracking Exposes Hidden Losses in Solar Water Splitting · Boosting a Protective Protein Halts Parkinson's-Linked Buildup in Mice · A Crater Nearly Split Mars's Moon Phobos in Two
